-1.74%
Today
Loading 1D prices…
Company profile
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Newport Beach, CA, United States
Employees
32
Fiscal year end
1231
CIK
1840563
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| SILOSilo Pharma Inc. Common Stock | $3.7M | $72.1K | -5863.50% | -$0.50 | -0.19% | Unrated |
| TCRTAlaunos Therapeutics Inc. Common Stock | $3.8M | $5K | -83520.00% | -$2.20 | -3.21% | Unrated |
| MBIOMustang Bio Inc. Common Stock | $3.8M | $0.00 | — | -$0.39 | -2.50% | Unrated |
| CVKDCadrenal Therapeutics Inc. Common Stock | $3.9M | $0.00 | — | -$6.64 | -7.63% | Buy |
| CDTCDT Equity Inc. Common Stock | $3.4M | $0.00 | — | -$1,177.89 | -27.54% | Unrated |